Skip to main content

PCRX

Stock
Health Care
Drug Manufacturers - Specialty & Generic

Performance overview

PCRX Price
Price Chart

Forward-looking statistics

Beta
1.55
Risk
60.50%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.

Company info

SectorHealth Care
IndustryDrug Manufacturers - Specialty & Generic
Employees745
Market cap$1.3B

Fundamentals

Enterprise value—
Revenue—
Revenue per employee—
Profit margin—
Debt to equity—

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)—
Dividend per share—
Revenue per share—
Avg trading volume (30 day)—
Avg trading volume (10 day)—
Put-call ratio—

Macro factor sensitivity

Growth+3.1
Credit+2.5
Liquidity-1.9
Inflation+0.1
Commodities+1.1
Interest Rates-1.1

Valuation

Dividend yield0.00%
PEG Ratio—
Price to sales—
P/E Ratio8.67
Enterprise Value to Revenue—
Price to book—

Upcoming events

Next earnings dayMay 9, 2025
Next dividend day—
Ex. dividend day—

News

Is the Options Market Predicting a Spike in Pacira BioSciences Stock?

Investors need to pay close attention to PCRX stock based on the movements in the options market lately.

Zacks Investment Research (June 18, 2025)
Pacira Settles Patent Dispute Over Exparel With Fresenius, Delays Pain Med' Generics Entry Until 2030, Stock Jumps

Pacira BioSciences, Inc. PCRX on Monday settled its litigations with Fresenius Kabi USA, Jiangsu Hengrui Pharmaceuticals Co., Ltd., and eVenus Pharmaceuticals Laboratories, Inc. related to patents for Exparel (bupivacaine liposome injectable suspension).

Benzinga (April 8, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free